The recent discovery that T-ALL with BRCA2 mutations were vulnerable to VE-821 and AZ6738 (48) confirms that reliable biomarkers of sensitivity to ATR inhibition would augment the clinical application of these agents in acute leukemias. Here, ATR is linked to acute lymphoblastic leukemia.